Last reviewed · How we verify

Rémifentamil + KETAMINE

University Hospital, Clermont-Ferrand · FDA-approved active Small molecule

Rémifentamil + KETAMINE is a Opioid + NMDA receptor antagonist combination Small molecule drug developed by University Hospital, Clermont-Ferrand. It is currently FDA-approved for Procedural sedation and anesthesia, Induction of general anesthesia.

Remifentanil and ketamine together provide rapid-onset anesthesia and analgesia by combining opioid mu-receptor agonism with NMDA receptor antagonism.

Remifentanil and ketamine together provide rapid-onset anesthesia and analgesia by combining opioid mu-receptor agonism with NMDA receptor antagonism. Used for Procedural sedation and anesthesia, Induction of general anesthesia.

At a glance

Generic nameRémifentamil + KETAMINE
SponsorUniversity Hospital, Clermont-Ferrand
Drug classOpioid + NMDA receptor antagonist combination
TargetMu-opioid receptor (remifentanil); NMDA receptor (ketamine)
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Remifentanil is a potent synthetic opioid agonist that binds mu-opioid receptors to produce analgesia and sedation with rapid onset and offset due to ester metabolism. Ketamine is a dissociative anesthetic that antagonizes NMDA glutamate receptors, producing anesthesia, analgesia, and dissociation. The combination provides synergistic anesthetic and analgesic effects suitable for procedural sedation and induction.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Rémifentamil + KETAMINE

What is Rémifentamil + KETAMINE?

Rémifentamil + KETAMINE is a Opioid + NMDA receptor antagonist combination drug developed by University Hospital, Clermont-Ferrand, indicated for Procedural sedation and anesthesia, Induction of general anesthesia.

How does Rémifentamil + KETAMINE work?

Remifentanil and ketamine together provide rapid-onset anesthesia and analgesia by combining opioid mu-receptor agonism with NMDA receptor antagonism.

What is Rémifentamil + KETAMINE used for?

Rémifentamil + KETAMINE is indicated for Procedural sedation and anesthesia, Induction of general anesthesia.

Who makes Rémifentamil + KETAMINE?

Rémifentamil + KETAMINE is developed and marketed by University Hospital, Clermont-Ferrand (see full University Hospital, Clermont-Ferrand pipeline at /company/university-hospital-clermont-ferrand).

What drug class is Rémifentamil + KETAMINE in?

Rémifentamil + KETAMINE belongs to the Opioid + NMDA receptor antagonist combination class. See all Opioid + NMDA receptor antagonist combination drugs at /class/opioid-nmda-receptor-antagonist-combination.

What development phase is Rémifentamil + KETAMINE in?

Rémifentamil + KETAMINE is FDA-approved (marketed).

What are the side effects of Rémifentamil + KETAMINE?

Common side effects of Rémifentamil + KETAMINE include Respiratory depression, Hypotension, Bradycardia, Dissociative effects, Emergence reactions.

What does Rémifentamil + KETAMINE target?

Rémifentamil + KETAMINE targets Mu-opioid receptor (remifentanil); NMDA receptor (ketamine) and is a Opioid + NMDA receptor antagonist combination.

Related